Osimertinib after Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and Post-progression Outcomes from the Phase III LAURA Study

发表于 6 天前

期刊：Clinical Cancer Research

文献作者：Mustafa Ozgüroglu; Myung-Ju Ahn; Xiaorong Dong; James Chih-Hsin Yang; Satoshi Oizumi; Koichi Goto; Manuel Cobo; Sang-We Kim; Te-Chun Hsia; Jarin Chindaprasirt; Fernanda Fujiki; Natalia Valdiviezo; Ignacio Casarini; Terufumi Kato; Xiangning Huang; Azura Evans; Elena Armenteros-Monterroso; Ana Bolanos; Suresh S. Ramalingam; Shun Lu

出版日期：--

DOI号：10.1158/1078-0432.ccr-25-4523

下载链接：https://aacrjournals.org/clincan ... 475/ccr-25-4523.pdf

文献链接：https://doi.org/10.1158/1078-0432.ccr-25-4523

当前文献来源于 American Association for Cancer Research (AACR)。

备注信息：

发表于 5 天前

: 当前求助处于待确认状态,请尽快下载
如果48小时后该求助仍未采纳，系统将自动采纳。

[AACR] Osimertinib after Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and Post-progression Outcomes from the Phase III LAURA Study

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[AACR] Osimertinib after Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and Post-progression Outcomes from the Phase III LAURA Study 一键复制